<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04229121</url>
  </required_header>
  <id_info>
    <org_study_id>CTC-FM</org_study_id>
    <nct_id>NCT04229121</nct_id>
  </id_info>
  <brief_title>Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients</brief_title>
  <official_title>Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Verify the Coincidence rate between Circulating tumor cells (CTCs) and tumor tissue or
      Circulating tumor DNA (ctDNA) of advanced NSCLC patients with Driver gene mutation
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Enrich CTCs from advanced Non-Small Cell Lung Cancer (NSCLC) patients with Driver gene
           mutation, and detect the Epidermal Growth Factor Receptor (EGFR) mutation, Anaplastic
           lymphoma kinase (ALK) fusion, ROS proto-oncogene receptor tyrosine kinase 1 (ROS1)
           fusion, RET proto-oncogene (RET) fusion and Mesenchymal-Epithelial Transition factor
           (MET) 14 exon skipping by Lung cancer Polymerase Chain Reaction (PCR) panel kit, and
           verify the mutation coincidence rate between CTCs and tumor tissue.

        2. Enrich ctDNA from advanced NSCLC patients with Driver gene mutation, detect the EGFR
           mutation by PCR, and detect the ALK fusion, ROS1 fusion, RET fusion and MET 14 exon
           skipping by next generation sequencing (NGS), and compare the mutation coincidence rate
           between CTCs and ctDNA.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Driver gene mutation frequency from CTCs of advanced NSCLC patients</measure>
    <time_frame>6 months</time_frame>
    <description>Analyze the driver gene mutation frequency in CTCs from advanced NSCLC patients with tumor tissue driver gene mutation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The gene mutation coincidence rate between CTCs and tumor tissue sample</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison the gene mutation coincidence rate between CTCs and tumor tissue sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Driver gene mutation frequency from ctDNA of advanced NSCLC patients</measure>
    <time_frame>6 months</time_frame>
    <description>Analyze the driver gene mutation frequency in ctDNA from advanced NSCLC patients with tumor tissue driver gene mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The gene mutation coincidence rate between CTCs and ctDNA</measure>
    <time_frame>6 months</time_frame>
    <description>Comparison the gene mutation coincidence rate between CTCs and ctDNA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced NSCLC</condition>
  <condition>Circulating Tumor Cells</condition>
  <condition>Circulating Tumor DNA</condition>
  <arm_group>
    <arm_group_label>Driver gene mutation-positive</arm_group_label>
    <description>Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation positive.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Driver gene mutation-negative</arm_group_label>
    <description>Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a Driver gene mutation negative.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nonintervention</intervention_name>
    <description>nonintervention</description>
    <arm_group_label>Driver gene mutation-negative</arm_group_label>
    <arm_group_label>Driver gene mutation-positive</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Histologially or cytologically proven diagnosis of advanced NSCLC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female or male, 18 years of age or older

          2. Histologically or cytologically proven diagnosis of advanced NSCLC patients without
             any target therapy or chemotherapy

          3. Able to get tumor tissue gene (EGFR/ALK/ROS1/RET/MET skipping) testing results by Lung
             cancer Polymerase Chain Reaction (PCR) panel kit carried out in hospital

          4. Signed and dated informed consent

        Exclusion Criteria:

          1. Combine with other tumor type

          2. The investigator judges the situation that may affect the clinical search process and
             results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yayi He, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital, Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yayi He, MD,PHD</last_name>
    <phone>+862165115006</phone>
    <email>2250601@qq.com</email>
  </overall_contact>
  <reference>
    <citation>Haber DA, Velculescu VE. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA. Cancer Discov. 2014 Jun;4(6):650-61. doi: 10.1158/2159-8290.CD-13-1014. Epub 2014 May 6. Review.</citation>
    <PMID>24801577</PMID>
  </reference>
  <reference>
    <citation>Li Y, Xu H, Su S, Ye J, Chen J, Jin X, Lin Q, Zhang D, Ye C, Chen C. Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS One. 2017 Aug 22;12(8):e0183331. doi: 10.1371/journal.pone.0183331. eCollection 2017. Erratum in: PLoS One. 2017 Dec 7;12 (12 ):e0189549.</citation>
    <PMID>28829813</PMID>
  </reference>
  <reference>
    <citation>Krebs MG, Metcalf RL, Carter L, Brady G, Blackhall FH, Dive C. Molecular analysis of circulating tumour cells-biology and biomarkers. Nat Rev Clin Oncol. 2014 Mar;11(3):129-44. doi: 10.1038/nrclinonc.2013.253. Epub 2014 Jan 21. Review.</citation>
    <PMID>24445517</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>January 10, 2020</last_update_submitted>
  <last_update_submitted_qc>January 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Caicun Zhou</investigator_full_name>
    <investigator_title>Director Head of Medical Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Cells, Circulating</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

